News

Mauna Kea Technologies Announces 2022 Nine Month Sales Results

27 October 2022

Global 9-month sales slightly down (5%) at €4.8 million while sales in the United States grew 23%

Mauna Kea Technologies today announced its sales results for the first nine months of 2022.

Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, commented: "Despite a challenging operating environment and the reallocation of resources associated with the strategic reorganization announced in late 2021, our commercial team has remained engaged and delivered satisfactory results, including 23% YTD growth in the United States.” Mr. Loiseau continued, “As I return to my executive leadership role, I am focused on improving the company's overall efficiency, capturing near-term growth opportunities and accelerating our development activities with strategic partners.”

​​​​For additional details and financial results, please see the full press release.

Latest News

Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management 

Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management 

Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform 

Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform 

Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 

Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise 

No results found.